BerGenBio ASA

The European biotech environment seems to be enjoying something of a revival but it has been a chastening week for three of the continent’s cancer-focused companies that have been forced to look at al

It has been shown for the first time that a combination of two different COVID-19 vaccines can produce high immunogenicity in patients, with no unexpected side-effects. On 18 May, Spain’s Carlos III I

Genmab A/S is not going to advance an antibody-drug conjugate, enapotamab vedotin, into late-stage clinical development, citing stringent proof-of-concept criteria, thereby cementing the biotech’s la

Two former US Food and Drug Administration commissioners – Mark McClellan and Scott Gottlieb – are among the most recent regulatory experts to join the international chorus calling for master protocol